195 related articles for article (PubMed ID: 21385922)
21. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
[TBL] [Abstract][Full Text] [Related]
24. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
[TBL] [Abstract][Full Text] [Related]
25. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
[TBL] [Abstract][Full Text] [Related]
26. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
28. Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Burnette BL; Jentoft MA; Porrata LF; Boyce TG; Witzig TE
J Clin Oncol; 2014 Mar; 32(7):e14-7. PubMed ID: 24395859
[No Abstract] [Full Text] [Related]
29. Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
Neuwelt EA; Barnett PA; McCormick CI; Remsen LG; Kroll RA; Sexton G
Clin Cancer Res; 1998 Jun; 4(6):1549-55. PubMed ID: 9626476
[TBL] [Abstract][Full Text] [Related]
30. Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma.
Soussain C; Muldoon LL; Varallyay C; Jahnke K; DePaula L; Neuwelt EA
Clin Cancer Res; 2007 Apr; 13(8):2504-11. PubMed ID: 17438111
[TBL] [Abstract][Full Text] [Related]
31. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
[TBL] [Abstract][Full Text] [Related]
32. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
[No Abstract] [Full Text] [Related]
33. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
34. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
[TBL] [Abstract][Full Text] [Related]
35. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
36. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
37. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
[TBL] [Abstract][Full Text] [Related]
38. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
39. Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Sato K; Uchiyama M
BMJ Case Rep; 2012 Jan; 2012():. PubMed ID: 22665914
[No Abstract] [Full Text] [Related]
40. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
Feugier P; Virion JM; Tilly H; Haioun C; Marit G; Macro M; Bordessoule D; Recher C; Blanc M; Molina T; Lederlin P; Coiffier B
Ann Oncol; 2004 Jan; 15(1):129-33. PubMed ID: 14679132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]